The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Cancer-derived exosomes as a delivery platform of CRISPR/Cas9 confer cancer cell tropism-dependent targeting
Abstract
An intracellular delivery system for CRISPR/Cas9 is crucial for its application as a therapeutic genome editing technology in a broad range of diseases. Current vehicles carrying CRISPR/Cas9 limit in vivo delivery because of low tolerance and immunogenicity; thus, the in vivo delivery of genome editing remains challenging. Here, we report that cancer-derived exosomes function as natural carriers that can efficiently deliver CRISPR/Cas9 plasmids to cancer. Compared to epithelial cell-derived exosomes, cancer-derived exosomes provide potential vehicles for effective in vivo delivery via selective accumulation in ovarian cancer tumors of SKOV3 xenograft mice, most likely because of their cell tropism. CRISPR/Cas9-loaded exosomes can suppress expression of poly (ADP-ribose) polymerase-1 (PARP-1), resulting in the induction of apoptosis in ovarian cancer. Furthermore, the inhibition of PARP-1 by CRISPR/Cas9-mediated genome editing enhances the chemosensitivity to cisplatin, showing synergistic cytotoxicity. Based on these results, tumor-derived exosomes may be very promising for cancer therapeutics in the future.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In another case, CRISPR/Cas9 technology has been loaded into synthetic exosomes to specifically target cancerous cells for gene editing, offering a potential new approach to treating genetic disorders and certain types of cancers [45].”
From Emerging role of exosomes in cancer therapy: progress and challenges (2025) · cites this paper as [45]
In the citing paper
“The CRISPR/Cas9-loaded exosomes significantly down-regulated PARP-1 expression, thus causing ovarian cancer cell death [54].”
From The Therapeutic Potential and Clinical Significance of Exosomes as Carriers of Drug Delivery System (2022) · cites this paper as [54]
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Exosomes: composition, biogenesis and function
Théry, C., Zitvogel, L., & Amigorena, S. (2002) · Nature reviews. Immunology · doi:10.1038/nri855 · Cited by 5,355
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes
Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., & Wood, M. J. A. (2011) · Nature Biotechnology · doi:10.1038/nbt.1807 · Cited by 4,930
DNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
CRISPR-Cas systems for editing, regulating and targeting genomes
Sander, J. D., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2842 · Cited by 3,153
Advances and Challenges of Liposome Assisted Drug Delivery
Sercombe, L., Veerati, T., Moheimani, F., Wu, S. Y., Sood, A. K., & Hua, S. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00286 · Cited by 2,672
Exosome and Exosomal MicroRNA: Trafficking, Sorting, and Function
Zhang, J., Li, S., Li, L., Li, M., Guo, C., Yao, J., & Mi, S. (2015) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2015.02.001 · Cited by 1,901
Systemically Injected Exosomes Targeted to EGFR Deliver Antitumor MicroRNA to Breast Cancer Cells
Ohno, S.-I., Takanashi, M., Sudo, K., Ueda, S., Ishikawa, A., Matsuyama, N., Fujita, K., Mizutani, T., Ohgi, T., Ochiya, T., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2012.180 · Cited by 1,666
Flagged first, then by citations
Cited by
Sorted by citations
RNA delivery by extracellular vesicles in mammalian cells and its applications
O’Brien, K., Breyne, K., Ughetto, S., Laurent, L. C., & Breakefield, X. O. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0251-y · Cited by 1,811
Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design
Vora, L. K., Gholap, A. D., Jetha, K. L., Singh, T. R. R., Solanki, H. K., & Chavda, V. P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071916 · Cited by 1,193
The role of extracellular vesicles in cancer
Kalluri, R., & McAndrews, K. M. (2023) · Cell · doi:10.1016/j.cell.2023.03.010 · Cited by 695
Exosomes─Nature’s Lipid Nanoparticles, a Rising Star in Drug Delivery and Diagnostics
Tenchov, R., Sasso, J. M., Wang, X., Liaw, W., Chen, C., & Zhou, Q. A. (2022) · ACS Nano · doi:10.1021/acsnano.2c08774 · Cited by 642
Emerging role of exosomes in cancer progression and tumor microenvironment remodeling
Paskeh, M. D. A., Entezari, M., Mirzaei, S., Zabolian, A., Saleki, H., Naghdi, M. J., Sabet, S., Khoshbakht, M. A., Hashemi, M., Hushmandi, K., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01305-4 · Cited by 591
Metadata
- Authors
- Kim, S. M., Yang, Y., Oh, S. J., Hong, Y., Seo, M., & Jang, M.
- Affiliations
- Korea Institute of Science and Technology (KR)
- Korea University (KR)
- Corresponding author
- Jang, Mihue
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2017-11
- Volume
- 266
- Pages
- 8-16
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2754835295
- Cited by
- 481
- References
- 39
- Citations by year
- 2026: 43 · 2025: 62 · 2024: 61 · 2023: 70 · 2022: 74 · 2021: 59 · 2020: 57 · 2019: 37 · 2018: 17 · 2017: 1
- FWCI
- 12.50
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Controlled Release (publishedVersion)
- PubMed (publishedVersion)
- Funders
- KIST (2E26910)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- tumor-derived exosomes, CRISPR/Cas9 delivery, ovarian cancer, apoptosis, cisplatin sensitivity, genome editing
- MeSH terms
- Poly (ADP-Ribose) Polymerase-1, Animals, Antineoplastic Agents, Cisplatin, Combined Modality Therapy, Female, Humans, Leukocytes, Mononuclear, Mice, Inbred BALB C, Mice, Nude, Neoplasms, RNA, Genetic Therapy, Cytokines, Gene Transfer Techniques, Cell Line, Tumor, Exosomes, HEK293 Cells, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
